News
ALKS
27.78
-0.93%
-0.26
Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?
Alkermes has grown its earnings per share by 29% in the last year. The company has a high level of insider ownership and is valued at US$66m. Alkermes is a good stock to follow because of its strong earnings growth. The firm has grown revenue by 3.1% over the past year. Insiders own a significant portion of the company, which is good for shareholders.
Simply Wall St · 15h ago
Strong Buy on Alkermes: Solid Q2 Earnings and Promising Drug Pipeline Drive Positive Outlook
TipRanks · 17h ago
Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
TipRanks · 19h ago
Guru Fundamental Report for ALKS
NASDAQ · 1d ago
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
NASDAQ · 1d ago
Alkermes Price Target Maintained With a $48.00/Share by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Benzinga · 1d ago
Alkermes Price Target Raised to $32.00/Share From $31.00 by JP Morgan
Dow Jones · 1d ago
Alkermes Is Maintained at Neutral by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $32
Benzinga · 1d ago
Alkermes Is Maintained at Outperform by Baird
Dow Jones · 1d ago
Alkermes Price Target Raised to $38.00/Share From $37.00 by Baird
Dow Jones · 1d ago
Baird Maintains Outperform on Alkermes, Raises Price Target to $38
Benzinga · 1d ago
Alkermes Price Target Raised to $37.00/Share From $35.00 by HC Wainwright & Co.
Dow Jones · 1d ago
Alkermes Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $37
Benzinga · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)
TipRanks · 1d ago
ALKERMES PLC <ALKS.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $37 FROM $35
Reuters · 1d ago
Strong Performance and Clinical Promise Uphold Buy Rating for Alkermes with $32 Target Price
Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Alkermes (ALKS – Research Report) and kept the price target at $32.00. The company reported second-quarter revenues that exceeded the analyst’s estimates. The firm is a biopharmaceutical company developing treatments for schizophrenia and alcohol dependence.
TipRanks · 1d ago
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
General Dynamics Corporation shares fell 5.2% to $279.26 on Wednesday. The company reported worse-than-expected second-quarter EPS results. NuZee, Inc. Shares jumped 192% after falling over 22% on Tuesday. Other stocks moving in the mid-day session included Tenet Healthcare Corporation and Mattel.
Benzinga · 2d ago
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.